Aβ/tau oligomer interplay at human synapses supports shifting therapeutic targets for Alzheimer's disease.

These results introduce the concept that TauO become the main synaptotoxic species at late AD, thus supporting the hypothesis that TauO may be the most effective therapeutic target for clinically manifest AD.